# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Emily Bodnar reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and maintains $28 pri...
Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroupsMedian PFS w...
Guggenheim analyst Brad Canino initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and announces Pri...
Oppenheimer analyst Matthew Biegler maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and maintains $22 price ...